Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 47 recruiting now early-phase tilt #108 of 28,707 conditions

Metastatic Cancer: early-phase trial registry

47 of 117 indexed Metastatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #108 of 28,707 conditions by registered trial count.

117 US clinical trials · 47 currently recruiting · #108 of 28,707 conditions by registered trial count

Metastatic Cancer: 117 US clinical trials tracked, 47 recruiting.

Metastatic Cancer is the subject of 117 registered US clinical trials on ClinicalTrials.gov, 47 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.

Enrollment posture brief

Registry condition metastatic-cancer

OPEN 47 | RECR 40% | LATE 8 | EARLY 87 | RANK #108 | SPON 11

Nearest open-share peer: Knee Osteoarthritis (40% recruiting · 102 trials)

Triple Negative Breast Cance57.1%Metastatic Cancer (this)40%Overweight and Obesity34.5%Diabetes Mellitus, Type 132.8%Weight Loss26.1%
Open-enrollment share among volume-matched conditions near Metastatic Cancer

Metastatic Cancer lists 47 open slots (40% of 117 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Cancer is recruiting above its size-band peers.

    47 of 117 indexed trials (40.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Metastatic Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 11 of 117 trials (9.4%). 80 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 110 trials that report a genuine target (sentinel values excluded). 70 of those (63.6%) plan for fewer than 100 participants.

  4. Metastatic Cancer research is mostly interventional.

    108 interventional and 9 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 154Phase 233Phase 38

Open and recent trials

117 total, page 3 of 3

COMPLETED Phase 1 24 participants

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Symphogen A/S

NCT03489343

COMPLETED Phase 1 14 participants

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

Akamis Bio

NCT05165433

COMPLETED Phase 1 12 participants

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

National Cancer Institute (NCI)

NCT04574583

COMPLETED Phase 1 12 participants

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00005616

COMPLETED Phase 1 12 participants

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

H. Lee Moffitt Cancer Center and Research Institute

NCT03758781

COMPLETED Phase 1 11 participants

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

University of Oklahoma

NCT00453050

COMPLETED Phase 1 9 participants

Stereotactic Radiation Therapy in Treating Patients With Liver Metastases

Mayo Clinic

NCT00567970

COMPLETED NA 6 participants

Balancing Method for Pain Related to Advanced Cancer

University of Pittsburgh

NCT04176575

COMPLETED Early Phase 1 6 participants

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

University of California, Irvine

NCT05555342

COMPLETED Phase 1 1 participants

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

National Cancer Institute (NCI)

NCT00301730

COMPLETED Phase 2

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Eastern Cooperative Oncology Group

NCT00003308

COMPLETED Phase 1

Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

NCT00012155

COMPLETED Phase 1

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT00020007

COMPLETED Phase 3

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Spectrum Pharmaceuticals

NCT00005887

COMPLETED Phase 2

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

National Cancer Institute (NCI)

NCT00103298

COMPLETED Phase 3

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

National Institutes of Health Clinical Center (CC)

NCT00020501

COMPLETED Phase 2

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

University of Washington

NCT00030563

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 54
Phase 2 33
Phase 3 8

Named interventions

Most-linked intervention names on Metastatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

quality-of-life assessment Procedure
5 trials
Nivolumab Drug
5 trials
Pembrolizumab Drug
5 trials
conventional surgery Procedure
4 trials
leucovorin calcium Drug
4 trials
fluorouracil Drug
4 trials
radiofrequency ablation Procedure
3 trials
irinotecan hydrochloride Drug
3 trials

US sites by state

Facility locations filed on Metastatic Cancer trials. A trial with sites in several states counts in each.

California 41 trials
New York 30 trials
Florida 29 trials
Texas 28 trials
Illinois 19 trials
Arizona 17 trials
Massachusetts 16 trials
Michigan 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Cancer page

117 registered trials, 47 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Cancer condition card totals 117 registered trials; most-linked intervention quality-of-life assessment; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.